Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

First drug-like compounds to inhibit elusive cancer-linked enzymes developed

First drug-like compounds to inhibit elusive cancer-linked enzymes developed

Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer

Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer

Immune protein IL-17A responsible for lethal side effects of gastric cancer

Immune protein IL-17A responsible for lethal side effects of gastric cancer

Researchers find potential to make brain cancers in children respond better to treatment

Researchers find potential to make brain cancers in children respond better to treatment

Phase 1 human trials suggest breast cancer drug is safe and effective

Phase 1 human trials suggest breast cancer drug is safe and effective

New data on emerging treatments for liver cancer raise hope for advanced disease patients

New data on emerging treatments for liver cancer raise hope for advanced disease patients

Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions

Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene...

New treatment possibilities for young women diagnosed with rare form of ovarian cancer

New treatment possibilities for young women diagnosed with rare form of ovarian cancer

New therapy targets breast cancer metastases in brain

New therapy targets breast cancer metastases in brain

Developing precise medicines for triple negative breast cancer

Developing precise medicines for triple negative breast cancer

More from ecancer